---
title: "12 Health Care Stocks Moving In Monday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296148353.md"
description: "During Monday's after-market session, several healthcare stocks experienced significant volatility. Gainers included INVO Fertility (+13.1%), Amylyx Pharmaceuticals (+11.99%), and Genprex (+11.19%). Conversely, losers featured DocGo (-14.1%), Gelteq (-7.38%), and Lexaria Bioscience (-7.08%). These movements followed the release of Q2 earnings for some companies."
datetime: "2026-08-17T21:06:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296148353.md)
  - [en](https://longbridge.com/en/news/296148353.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296148353.md)
---

# 12 Health Care Stocks Moving In Monday's After-Market Session

### Gainers

-   **INVO Fertility** (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out today.
-   **Amylyx Pharmaceuticals** (NASDAQ:AMLX) shares moved upwards by 11.99% to $24.0. The market value of their outstanding shares is at $2.4 billion.
-   **Genprex** (NASDAQ:GNPX) stock rose 11.19% to $4.98. The market value of their outstanding shares is at $2.1 million.
-   **TransCode Therapeutics** (NASDAQ:RNAZ) shares increased by 9.49% to $3.46. The market value of their outstanding shares is at $3.4 million.
-   **China SXT Pharmaceuticals** (NASDAQ:SXTC) shares increased by 6.66% to $4.0. The market value of their outstanding shares is at $2.3 million.
-   **YD Bio** (NASDAQ:YDES) stock moved upwards by 6.52% to $3.59. The company's market cap stands at $211.0 million.

### Losers

-   **DocGo** (NASDAQ:DCGO) stock fell 14.1% to $0.61 during Monday's after-market session. The company's market cap stands at $65.9 million. The company's, Q2 earnings came out today.
-   **Gelteq** (NASDAQ:GELS) stock declined by 7.38% to $0.52. The company's market cap stands at $6.2 million.
-   **Lexaria Bioscience** (NASDAQ:LEXX) shares fell 7.08% to $9.59. The company's market cap stands at $14.9 million.
-   **iTonic Holdings** (NASDAQ:ITOC) shares declined by 5.91% to $0.26. The market value of their outstanding shares is at $5.3 million.
-   **Exicure** (NASDAQ:XCUR) stock fell 5.8% to $1.3. The market value of their outstanding shares is at $7.9 million.
-   **Apimeds Pharmaceuticals** (AMEX:APUS) shares decreased by 5.15% to $4.06. The company's market cap stands at $6.8 million. As per the press release, Q2 earnings came out yesterday. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [LEXX.US](https://longbridge.com/en/quote/LEXX.US.md)
- [GELS.US](https://longbridge.com/en/quote/GELS.US.md)
- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)
- [IVF.US](https://longbridge.com/en/quote/IVF.US.md)
- [GNPX.US](https://longbridge.com/en/quote/GNPX.US.md)
- [DCGO.US](https://longbridge.com/en/quote/DCGO.US.md)
- [RNAZ.US](https://longbridge.com/en/quote/RNAZ.US.md)
- [SXTC.US](https://longbridge.com/en/quote/SXTC.US.md)
- [YDES.US](https://longbridge.com/en/quote/YDES.US.md)
- [ITOC.US](https://longbridge.com/en/quote/ITOC.US.md)
- [XCUR.US](https://longbridge.com/en/quote/XCUR.US.md)
- [APUS.US](https://longbridge.com/en/quote/APUS.US.md)
- [YDESW.US](https://longbridge.com/en/quote/YDESW.US.md)
- [LEXXW.US](https://longbridge.com/en/quote/LEXXW.US.md)

## Related News & Research

- [AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial](https://longbridge.com/en/news/296265581.md)
- [AMLX: Avexitide achieved a 55% reduction in severe hypoglycemic events in PBH, with strong safety data](https://longbridge.com/en/news/296234006.md)
- [Amylyx Says Phase 3 Trial of Avexitide For Post-Bariatric Hypoglycemia Met Main Goal](https://longbridge.com/en/news/296218787.md)
- [Amylyx to release Phase 3 LUCIDITY trial topline results for avexitide in post-bariatric hypoglycemia Aug. 18, 2026](https://longbridge.com/en/news/296140552.md)
- [Genprex signs CDMO deal to scale up manufacturing for diabetes gene therapy program](https://longbridge.com/en/news/296218198.md)